Avacta Group PLC Capital Markets Day Notification
January 08 2018 - 1:00AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
08 January 2018
8 January 2018
Avacta Group plc
("Avacta", "the Group" or "the Company")
Capital Markets Day Notification
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and reagents, today announces that it will host a
Capital Markets Day for financial analysts and institutional
investors on Wednesday, 7 February 2018 from 2pm to 4pm at
finnCap's offices, 60 New Broad St, London, EC2M 1JJ.
The event will begin with a non-technical corporate update by
Alastair Smith, Chief Executive Officer on strategy, key technical
milestones and value inflection points and emerging themes within
the business.
Following this update there will also be an opportunity to speak
with other members of the Senior Management Team, whilst
refreshments are served.
No new material information will be disclosed during the
event.
If you would like to attend, please contact
investorevents@avacta.com.
The presentation materials will be made available on the Group's
website www.avacta.com
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane / Nikita
Jain - Corporate Broking
Tel: +44 (0)
WG Partners 203 705 9318
Nigel Birks / Nigel Barnes Tel: +44 (0)
David Wilson / Claes Spang 203 705 9217
www.wgpartners.co.uk
Zyme Communications (Trade and Tel: +44 (0)7787
Regional Media) 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
Yellow Jersey PR (Financial Media Tel: +44 (0)7764
and IR) 947137
Sarah Hollins avacta@yellowjerseypr.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUMUGUPRGMP
(END) Dow Jones Newswires
January 08, 2018 02:00 ET (07:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024